Drug resistance and antiretroviral drug development.
As more drugs for treating HIV have become available, drug resistance profiles within antiretroviral drug classes have become increasingly important for researchers developing new drugs and for clinicians integrating new drugs into their clinical practice. In vitro passage experiments and comprehensive phenotypic susceptibility testing are used for the pre-clinical evaluation of drug resistance. Clinical studies are required, however, to delineate the full spectrum of mutations responsible for resistance to a new drug and to identify the settings in which a new drug is likely to be most useful for salvage therapy.
Shafer
Robert W
RW
Division of Infectious Diseases, Department of Medicine, Stanford University, Stanford, CA 94305, USA. rshafer@stanford.edu
Schapiro
Jonathan M
JM
D019380:Anti-HIV Agents / Q000494:pharmacology*; D015195:Drug Design; D024882:Drug Resistance, Viral; D004359:Drug Therapy, Combination; D005838:Genotype; D006801:Humans; D010641:Phenotype
D019380:Anti-HIV Agents